search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Real world data collection and population-based analysis of incidence of patients with acute myeloid leukemia (AML).


- candidate number25376
- NTR NumberNTR6105
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR6-okt-2016
- Secondary IDsRTPO980a VZ-NI-OTHER-Hemobase-007339
- Public TitleReal world data collection and population-based analysis of incidence of patients with acute myeloid leukemia (AML).
- Scientific TitleReal world data collection and population-based analysis of incidence of patients with acute myeloid leukemia (AML).
- ACRONYM
- hypothesisThe hypothesis: the overall survival of AML patients is influenced by AML type, age, genetic aberrancies, comorbidity and performance status of the patient as well as type of treatment.
- Healt Condition(s) or Problem(s) studiedAcute Myeloid Leukemia (AML)
- Inclusion criteriaretrospective observational population-based; all patients in Friesland
- Exclusion criteriaretrospective observational population-based; all patients in Friesland
- mec approval receivedyes
- multicenter trialno
- randomisedno
- group[default]
- Type[default]
- Studytypeobservational
- planned startdate 1-jan-2016
- planned closingdate31-dec-2017
- Target number of participants200
- Interventionsnone
- Primary outcomenone
- Secondary outcomenone
- Timepoints31-12-2017
- Trial web site
- status[default]
- CONTACT FOR PUBLIC QUERIESDr. M. Hoogendoorn
- CONTACT for SCIENTIFIC QUERIESDr. M. Hoogendoorn
- Sponsor/Initiator Stichting HemoBase
- Funding
(Source(s) of Monetary or Material Support)
Celgene
- Publications
- Brief summaryAcute myeloid leukemia (AML) is a heterogeneous hematopoietic stem cell disease characterised by a proliferation of myeloblasts in the bone marrow. The incidence is 3 to 4 per 100.000. AML is a heterogeneous disease with may subtypes showing large differences in age, comorbidity, performance status and treatment of the patient.
- Main changes (audit trail)
- RECORD6-okt-2016 - 27-nov-2016


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl